Malignant Superior Vena Cava Syndrome : State of the Art
Copyright © 2022, Patriarcheas et al..
Superior vena cava syndrome (SVCS) is a clinical entity characterized by signs and symptoms arising from the obstruction or occlusion of the thin-walled superior vena cava (SVC) and can result in significant morbidity and mortality. Despite the rise of benign cases of SVCS, as a thrombotic complication of intravascular devices, it is most commonly seen secondary to malignancy as a consequence of thrombosis, direct invasion of tumor cells inside the vessel, or external compression. SVCS can be the initial presentation of a previously undiagnosed tumor in up to 60% of cases. Lung cancer and non-Hodgkin lymphoma (NHL) are responsible for up to 85%-90% of malignancy-related SVCS, while metastatic cancers account for approximately 10%. Herein, we review the pathophysiology, etiology, clinical presentation, diagnosis, and management of malignancy-related SVCS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cureus - 14(2022), 1 vom: 01. Jan., Seite e20924 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patriarcheas, Vasileios [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 11.01.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.20924 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335393438 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335393438 | ||
| 003 | DE-627 | ||
| 005 | 20231225225734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.20924 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335393438 | ||
| 035 | |a (NLM)35004083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patriarcheas, Vasileios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Malignant Superior Vena Cava Syndrome |b State of the Art |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.01.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022, Patriarcheas et al. | ||
| 520 | |a Superior vena cava syndrome (SVCS) is a clinical entity characterized by signs and symptoms arising from the obstruction or occlusion of the thin-walled superior vena cava (SVC) and can result in significant morbidity and mortality. Despite the rise of benign cases of SVCS, as a thrombotic complication of intravascular devices, it is most commonly seen secondary to malignancy as a consequence of thrombosis, direct invasion of tumor cells inside the vessel, or external compression. SVCS can be the initial presentation of a previously undiagnosed tumor in up to 60% of cases. Lung cancer and non-Hodgkin lymphoma (NHL) are responsible for up to 85%-90% of malignancy-related SVCS, while metastatic cancers account for approximately 10%. Herein, we review the pathophysiology, etiology, clinical presentation, diagnosis, and management of malignancy-related SVCS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a endovascular therapy | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a malignancy-related superior vena cava syndrome | |
| 650 | 4 | |a non-hodgkin lymphoma (nhl) | |
| 650 | 4 | |a superior vena cava obstruction | |
| 650 | 4 | |a superior vena cava syndrome | |
| 650 | 4 | |a thoracic oncology | |
| 700 | 1 | |a Grammoustianou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Ptohis, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Thanou, Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Kostis, Minas |e verfasserin |4 aut | |
| 700 | 1 | |a Gkiozos, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Charpidou, Andriani |e verfasserin |4 aut | |
| 700 | 1 | |a Trontzas, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Syrigos, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Kotteas, Elias |e verfasserin |4 aut | |
| 700 | 1 | |a Dimakakos, Evangelos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 14(2022), 1 vom: 01. Jan., Seite e20924 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:e20924 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.20924 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 1 |b 01 |c 01 |h e20924 | ||